Impact of renal function on admission in COVID-19 patients: an analysis of the international HOPE COVID-19 (Health Outcome Predictive Evaluation for COVID 19) Registry.


Journal

Journal of nephrology
ISSN: 1724-6059
Titre abrégé: J Nephrol
Pays: Italy
ID NLM: 9012268

Informations de publication

Date de publication:
08 2020
Historique:
received: 06 05 2020
accepted: 22 06 2020
pubmed: 1 7 2020
medline: 11 8 2020
entrez: 1 7 2020
Statut: ppublish

Résumé

Coronavirus disease 2019 (COVID-19) is a disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Despite its international aggressive extension, with a significant morbidity and mortality, the impact of renal function on its prognosis is uncertain. Analysis from the international HOPE-Registry (NCT04334291). The objective was to evaluate the association between kidney failure severity on admission with the mortality of patients with SARS-CoV-2 infection. Patients were categorized in 3 groups according to the estimated glomerular filtration rate on admission (eGFR > 60 mL/min/1.73 m 758 patients were included: mean age was 66 ± 18 years, and 58.6% of patient were male. Only 8.5% of patients had a history of chronic kidney disease (CKD); however, 30% of patients had kidney dysfunction upon admission (eGFR < 60 mL/min/1.73 m Renal failure on admission in patients with SARS-CoV-2 infection is frequent and is associated with a greater number of complications and in-hospital mortality. Our data comes from a multicenter registry and therefore does not allow to have a precise mortality risk assessment. More studies are needed to confirm these findings.

Sections du résumé

BACKGROUND
Coronavirus disease 2019 (COVID-19) is a disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Despite its international aggressive extension, with a significant morbidity and mortality, the impact of renal function on its prognosis is uncertain.
METHODS
Analysis from the international HOPE-Registry (NCT04334291). The objective was to evaluate the association between kidney failure severity on admission with the mortality of patients with SARS-CoV-2 infection. Patients were categorized in 3 groups according to the estimated glomerular filtration rate on admission (eGFR > 60 mL/min/1.73 m
RESULTS
758 patients were included: mean age was 66 ± 18 years, and 58.6% of patient were male. Only 8.5% of patients had a history of chronic kidney disease (CKD); however, 30% of patients had kidney dysfunction upon admission (eGFR < 60 mL/min/1.73 m
CONCLUSIONS
Renal failure on admission in patients with SARS-CoV-2 infection is frequent and is associated with a greater number of complications and in-hospital mortality. Our data comes from a multicenter registry and therefore does not allow to have a precise mortality risk assessment. More studies are needed to confirm these findings.

Identifiants

pubmed: 32602006
doi: 10.1007/s40620-020-00790-5
pii: 10.1007/s40620-020-00790-5
pmc: PMC7322375
doi:

Substances chimiques

Peptidyl-Dipeptidase A EC 3.4.15.1
ACE2 protein, human EC 3.4.17.23
Angiotensin-Converting Enzyme 2 EC 3.4.17.23

Banques de données

ClinicalTrials.gov
['NCT04334291']

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

737-745

Références

Virol Sin. 2020 Jun;35(3):266-271
pubmed: 32125642
N Engl J Med. 2020 Apr 30;382(18):1708-1720
pubmed: 32109013
J Nephrol. 2020 Jun;33(3):401-403
pubmed: 32323202
J Nephrol. 2020 Apr;33(2):193-196
pubmed: 32207068
Semin Immunopathol. 2017 Jul;39(5):529-539
pubmed: 28466096
Microbiol Mol Biol Rev. 2012 Mar;76(1):16-32
pubmed: 22390970
J Korean Med Sci. 2016 Apr;31(4):635-40
pubmed: 27051251
Kidney Int. 2005 Feb;67(2):698-705
pubmed: 15673319
Lancet. 2020 Feb 15;395(10223):514-523
pubmed: 31986261
BMC Nephrol. 2016 Dec 12;17(1):199
pubmed: 27955633
Lancet. 2020 Mar 28;395(10229):1054-1062
pubmed: 32171076
Lancet. 2003 May 24;361(9371):1767-72
pubmed: 12781535
Intensive Care Med. 2020 Jun;46(6):1114-1116
pubmed: 32236644
J Nephrol. 2020 Jun;33(3):393-395
pubmed: 32277423
JAMA. 2020 Feb 7;:
pubmed: 32031570
Kidney Int. 2020 Jul;98(1):219-227
pubmed: 32327202
Lancet. 2020 Feb 15;395(10223):497-506
pubmed: 31986264
Viruses. 2020 Mar 27;12(4):
pubmed: 32230900
J Heart Lung Transplant. 2020 May;39(5):405-407
pubmed: 32362390
Nat Rev Nephrol. 2013 May;9(5):255-65
pubmed: 23507826

Auteurs

Aitor Uribarri (A)

Instituto de Ciencias del Corazón (ICICOR), CIBER-CV, Hospital Clínico Universitario de Valladolid, C/Ramón y Cajal 3, 47005, Valladolid, Spain. auribarrig@gmail.com.

Iván J Núñez-Gil (IJ)

Hospital Clínico San Carlos, Universidad Complutense de Madrid, Instituto de Investigación Sanitaria del Hospital Clínico San Carlos (IdISSC), Madrid, Spain.

Alvaro Aparisi (A)

Instituto de Ciencias del Corazón (ICICOR), CIBER-CV, Hospital Clínico Universitario de Valladolid, C/Ramón y Cajal 3, 47005, Valladolid, Spain.

Victor M Becerra-Muñoz (VM)

Unidad de Gestión Clínica Área del Corazón, Instituto de Investigación Biomédica de Málaga (IBIMA), Hospital Universitario Virgen de la Victoria, Universidad de Málaga (UMA), Centro de Investigación Biomédica en Red de Enfermedades Cardiovasculares (CIBERCV), Málaga, Spain.

Gisela Feltes (G)

Hospital Nuestra Señora de América, Madrid, Spain.

Daniela Trabattoni (D)

Centro Cardiologico Monzino, IRCCS, Milan, Italy.

Inmaculada Fernández-Rozas (I)

Hospital Severo Ochoa, Leganés, Spain.

María C Viana-Llamas (MC)

Hospital Universitario Guadalajara, Guadalajara, Spain.

Martino Pepe (M)

Azienda Ospedaliero-Universitaria Consorziale Policlinico di Bari, Bari, Italy.

Enrico Cerrato (E)

San Luigi Gonzaga University Hospital, Rivoli, Turin, Italy.

Thamar Capel-Astrua (T)

Hospital Virgen del Mar, Madrid, Spain.

Rodolfo Romero (R)

Hospital Universitario Getafe, Madrid, Spain.

Alex F Castro-Mejía (AF)

Hospital General del norte de Guayaquil IESS Los Ceibos, Guayaquil, Ecuador.

Ibrahim El-Battrawy (I)

First Department of Medicine, Medical Faculty Mannheim, University Heidelberg, Mannheim, 68167, Germany.
DZHK (German Center for Cardiovascular Research), Partner Site, Heidelberg-Mannheim, Mannheim, Germany.

Javier López-País (J)

Complejo Hospitalario Universitario de Santiago de Compostela Santiago de Compostela, Santiago de Compostela, Spain.

Fabrizio D'Ascenzo (F)

San Giovanni Battista, Turin, Italy.

Oscar Fabregat-Andres (O)

Hospital IMED, Valencia, Spain.

Alfredo Bardají (A)

University Hospital Joan XXIII, Tarragona, Spain.

Sergio Raposeiras-Roubin (S)

University Hospital Álvaro Cunqueiro, Vigo, Spain.

Francisco Marín (F)

Hospital Clínico Universitario Virgen de la Arrixaca, IMIB-Arrixaca, Universidad de Murcia, CIBERCV, Murcia, Spain.

Antonio Fernández-Ortiz (A)

Hospital Clínico San Carlos, Universidad Complutense de Madrid, Instituto de Investigación Sanitaria del Hospital Clínico San Carlos (IdISSC), Madrid, Spain.

Carlos Macaya (C)

Hospital Clínico San Carlos, Universidad Complutense de Madrid, Instituto de Investigación Sanitaria del Hospital Clínico San Carlos (IdISSC), Madrid, Spain.

Vicente Estrada (V)

Hospital Clínico San Carlos, Universidad Complutense de Madrid, Instituto de Investigación Sanitaria del Hospital Clínico San Carlos (IdISSC), Madrid, Spain.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH